Events

Conference: Quantum Europe 2025
OCT
Wed
01
09:00 - 17:00

Starts in 2 months from now

Location

Brussels

Programmes
Digital, Industry & Space

Forum Europe is re-organising their Quantum Europe Conference this year. 

This year's conference will explore the EU's expanding quantum agenda, including initiatives such as the Quantum Flagship, EuroQCI, EU Quantum Strategy and forthcoming EU Quantum Act. Topics will also cover the impact of quantum technologies on cybersecurity, future communications, industrial adoption, and the ongoing tension between international cooperation and technological sovereignty.

This is a paid event!

You can find more information here and register here.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.